Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZNCF) Assets Average (2016 - 2025)

Historic Assets Average for Astrazeneca (AZNCF) over the last 17 years, with Q4 2025 value amounting to $114.3 billion.

  • Astrazeneca's Assets Average rose 936.7% to $114.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $114.3 billion, marking a year-over-year increase of 936.7%. This contributed to the annual value of $109.1 billion for FY2025, which is 631.48% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Assets Average is $114.3 billion, which was up 936.7% from $113.4 billion recorded in Q3 2025.
  • Astrazeneca's Assets Average's 5-year high stood at $114.3 billion during Q4 2025, with a 5-year trough of $50.2 billion in Q1 2022.
  • Over the past 5 years, Astrazeneca's median Assets Average value was $97.5 billion (recorded in 2022), while the average stood at $92.8 billion.
  • In the last 5 years, Astrazeneca's Assets Average plummeted by 1355.07% in 2022 and then soared by 9244.45% in 2023.
  • Astrazeneca's Assets Average (Quarter) stood at $53.7 billion in 2021, then surged by 77.65% to $95.3 billion in 2022, then increased by 3.43% to $98.6 billion in 2023, then increased by 5.96% to $104.5 billion in 2024, then rose by 9.37% to $114.3 billion in 2025.
  • Its Assets Average stands at $114.3 billion for Q4 2025, versus $113.4 billion for Q3 2025 and $109.3 billion for Q2 2025.